Alzheimer’s disease gradually worsens over time, and there’s no cure for it yet. Leqembi (lecanemab) is a new type of medicine that can slow down how quickly Alzheimer’s disease gets worse.

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

Leqembi — sold through a partnership between Eisai and Cambridge-based Biogen Inc. — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a ...

The study results on Leqembi, which Eisai shares with Biogen, also found that a patient's Alzheimer's disease worsens after they stop treatment. Rates of adverse side effects associated with ...

A new Fujirebio Diagnostics blood test identifies beta-amyloid, a brain plaque that is a key marker for Alzheimer’s disease.

Two new drugs targeting early-stage Alzheimer’s disease are expected to be put into clinical use as soon as Thursday next ...

NewAmsterdam Pharma has said that an oral drug it is developing to lower cholesterol has shown preliminary efficacy as a ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders ...

The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term. That's according to new data ...